Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.727
Index Copernicus  – 166.39
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 1, January-February, p. 103–111

doi: 10.17219/acem/38154

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Evaluation of the Toxicity of Anticancer Chemotherapy in Patients with Colon Cancer

Anna Wiela-Hojeńska1,A,C,D,E,F, Teresa Kowalska1,B,C,D, Emilia Filipczyk-Cisarż2,B,C,F, Łukasz Łapiński1,A,B,E,F, Karol Nartowski1,B

1 Department of Clinical Pharmacology, Wroclaw Medical University, Poland

2 Department of Chemotherapy, Lower Silesian Oncology Center, Wrocław, Poland


Background. Modern anticancer chemotherapy can cause numerous adverse effects in the organism, whose functioning has already been disrupted by the neoplastic process itself.
Objectives. The aim of the study was to evaluate and compare the frequency and severity of the toxicity of FOLFOX-4 and CLF-1 anticancer therapy in patients with colon cancer, and to analyze certain factors that might have increased the toxicity of the chemotherapy.
Material and Methods. The study involved 64 patients suffering from generalized colon cancer, including 48 patients treated according to the FOLFOX-4 regimen and 16 patients treated according to the CLF-1 regimen. The toxicity of each regimen was analyzed on the basis of a confidential questionnaire formulated by the authors and laboratory research according to the extended WHO toxicity criteria.
Results. The analysis of the symptoms of toxicity symptoms associated with the use of the FOLFOX-4 and CLF-1 therapeutic regimens revealed that the most common side effects included nausea and vomiting, despite ondansetron premedication, and neurotoxicity. Disruption of the functioning of the nervous system under the FOLFOX-4 regimen statistically significant exacerbation that increased with the number of chemotherapy cycles administered; this was more common and more severe in women. Paresthesia was also revealed to be a neurotoxic effect of the FOLFOX-4 regimen after termination of therapy. A statistically significant relationship was observed between the use of vitamin supplements and the incidence and severity of the toxicity of the FOLFOX-4 regimen.
Conclusion. The findings of the current study regarding the toxicity of the FOLFOX-4 and CLF-1 therapy regimens should be taken into consideration when monitoring chemotherapy safety in colon cancer. The patients’ tolerance of the administered medication and the side effects reported by patients should be constantly evaluated, which will help prevent these side effects, apply appropriate therapy and contribute to the improvement of the patients’ quality of life. The functioning of the central nervous system should be carefully evaluated when planning the anticancer therapy, especially if repeated administration of neurotoxic drugs is necessary in cases of a recurrence of the disease. Chemotherapy should be thoroughly monitored for safety, especially in women over 65 years of age suffering from coexisting diseases. Colon cancer patients and their families should be informed of the risks of nutritional supplements before the start of the anticancer chemotherapy, and may need to dispense with their use

Key words

FOLFOX-4, CLF-1, chemotherapy, toxicity, colon cancer.

References (18)

  1. Orzechowska-Juzwenko K: Zarys chemioterapii nowotworów narządowych i układowych. Volumed, Wrocław, 2000.
  2. Krzemieniecki K: Leczenie wspomagające w onkologii, Termedia Wydawnictwa Medyczne, Poznań 2008.
  3. Cleeland CS, Allen JD, Roberts SA, Brell JM, Giralt SA, Khakoo AY, Kirch RA, Kwitkowski VE, Liao Z, Skillings J: Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nat Rev Clin Oncol 2012, 9, 471–478.
  4. Ramesh A: Toxicities of anticancer drugs and its managment. Int J Basic Clin Pharmacol 2012, 1, 2–12.
  5. Gotay C, Kawamoto CT, Bottomley A, Efficace F: The prognostic significance of patient-reported outcomesin cancer clinical trials. J Clin Oncol 2008, 26, 1355–1363.
  6. Bash E, Artz D, Dulko D, Schrag D: Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol 2005, 23, 3552–3561.
  7. Ruhstaller T, von Moos R, Rufibach K, Ribi K, Glaus A, Spaeti B, Koeberle D, Mueller U, Hoefliger M, Hess D, Boehme C, Thuerlimann B: Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: An outcome research study. Oncology 2009, 76, 142–148.
  8. Basch E, Iasonos A, Bar A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, Mc Cabe M, Schrag D: Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol 2007, 25, 5374–5380.
  9. Tournigand C, Andre T, Achille E, Ledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004, 22, 229–237.
  10. Dranitsaris G, Shah A, Spirovski B, Vincent M: Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool. Clin Colorectal Cancer 2007, 6, 367–373.
  11. Porębski G, Woroń J, Krzemieniecki K: Reakcje nadwrażliwości i desensytyzacja na leki w onkologii. Onkol Prakt Klin 2009, 5, 244–249.
  12. Skif W, Roy S, Ledbetter L, Madison J, Syrigos K: Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colonorectal cancer. Oxaliplatin-induced hypersensitivity reaction. World J Gastroenterol 2007, 13, 5277–5281.
  13. Shibata Y, Ariyama H, Baba E, Takii Y, Esaki T, Mitsugi K, Tsuchiya T, Kusaba H, Akashi K, Nakano S: Oxaliplatin-induced allergic reaction in patients with colorectal cancer. Int J Clin Oncol 2009, 14, 397–401.
  14. Hidebrand J: Neurological complications of cancer chemotherapy. Curr Opin Oncol 2006, 18, 321–324.
  15. Petrioli R, Pascucci A, Francini E, Marsili S, Sciandivasci A, Tassi R, Civitelli S, Tanzini G, Lorenzi M, Francini G: Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedule of oxaliplatin. Cancer Chemother Pharmacol 2008, 61, 105–111.
  16. Sokol KC, Knudsen JF: Polypharmacy in older oncology patients and the need for interdisciplinary approach to side-effect managment. J Clin Pharm Ther 2007, 32, 169–175.
  17. Figer A, Perez-Staub N, Carola E, Tournigrand C, Lledo G, Flesch M, Barcelo R, Cervantes A, Andre T, Colin P, Louvet C, de Gramont A: FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX 1 study. Cancer 2007, 110, 2666–2671.
  18. Gamelin L, Boisdron-Celle M, Delva R, Gue’rin-Meyer V, Ifrah N, Morel A, Gamelan A: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004, 10, 4055–4061.